ArticlemSphere2025
Development of blood-brain barrier-penetrating antibodies for neutralizing tick-borne encephalitis virus in the brain.
Mizuki Fukuta, Sayo Fukano, Naoya Maekawa, Shintaro Kobayashi, Shunsuke Okamoto, Minato Hirano, Junko Nio-Kobayashi, Hiroaki Kariwa, Shigeru Kawakami, Satoru Konnai and 1 more
Abstract read
In one paragraphArticle in mSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Mizuki FukutaDepartment of Viral Ecology, National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University, Nagasaki, Japan.ORCID 0009-0009-3057-755X Sayo FukanoLaboratory of Public Health, Faculty of Veterinary Medicine, Hokkaido University, Hokkaido, Japan.
Naoya MaekawaDepartment of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan.
Shintaro KobayashiLaboratory of Public Health, Faculty of Veterinary Medicine, Hokkaido University, Hokkaido, Japan.
Shunsuke OkamotoDepartment of Viral Ecology, National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University, Nagasaki, Japan.
Minato HiranoDepartment of Viral Ecology, National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University, Nagasaki, Japan.
Junko Nio-KobayashiDepartment of Functional Glycobiology in Infectious Diseases, National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University, Nagasaki, Japan.
Hiroaki KariwaLaboratory of Public Health, Faculty of Veterinary Medicine, Hokkaido University, Hokkaido, Japan.
Shigeru KawakamiDepartment of Pharmaceutical Informatics, Graduate School of Biomedical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Satoru KonnaiDepartment of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan.ORCID 0000-0002-3230-7109 Kentaro YoshiiDepartment of Viral Ecology, National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University, Nagasaki, Japan.ORCID 0000-0002-1104-0898 Funding
Japan Agency for Medical Research and Development JP24fm0208101,JP23fk0108614,JP23wm0325059Japan Society for the Promotion of Science 20H03136,21KK0123,21K19191,23K27079Japan Society for the Promotion of Science 21K20761,22K15012Japan Society for the Promotion of Science 23KJ1760
6 · The paper itselfAbstract
Tick-borne encephalitis virus (TBEV) belongs to the genus IMPORTANCE: Tick-borne encephalitis virus is a neuroinvasive pathogen that causes severe neurologic disease, significantly affecting patients' quality of life. No specific antiviral treatment is available for tick-borne encephalitis caused by virus multiplication in the brain. The delivery of drugs to the brain via peripheral administration is often obstructed by the blood-brain barrier. To develop targeted antiviral therapies for brain infections, we engineered recombinant antibodies capable of crossing the blood-brain barrier via brain-targeted ligands. These antibodies exhibited permeability across the blood-brain barrier in both
Indexed as
Antibodies, NeutralizingAntibodies, ViralBlood-Brain BarrierBrainEncephalitis, Tick-BorneEncephalitis Viruses, Tick-BorneAnimalsCell LineEndothelial CellsFemaleGlycoproteinsHumansMiceMice, Inbred BALB CPeptide FragmentsRecombinant Fusion ProteinsAntibodies, NeutralizingAntibodies, ViralGlycoproteinsPeptide Fragmentsrabies virus glycoprotein peptideRecombinant Fusion ProteinsViral Proteinsblood-brain barrierrabies virus glycoproteinrecombinant antibodytick-borne encephalitis virus
Identifiers
PMID40622136
PMCPMC12306175
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390